Intel stock spikes after report of possible US government stake
Investing.com - H.C. Wainwright lowered its price target on UroGen Pharma (NASDAQ:URGN) to $40.00 from $50.00 on Monday, while maintaining a Buy rating on the stock. According to InvestingPro data, the company maintains impressive gross profit margins of 89%, though it’s currently experiencing rapid cash burn.
The firm adjusted its target following UroGen’s second-quarter 2025 financial results, which showed revenue of $24.2 million, falling short of H.C. Wainwright’s forecast of $25.9 million. Despite this miss, JELMYTO, the company’s treatment for upper tract urothelial carcinoma, delivered 11% year-over-year revenue growth, aligning with the company’s overall revenue growth rate of 11% over the last twelve months.
H.C. Wainwright revised its full-year 2025 revenue forecast for UroGen to $106 million from $112.1 million previously, while its 2026 revenue estimate was reduced to $249.9 million from $292.1 million. The firm also widened its projected 2025 net loss to $3.37 per share from $3.10 per share.
The analyst firm expressed optimism about ZUSDURI (formerly UGN-102), UroGen’s recently approved treatment for low-grade, intermediate-risk non-muscle-invasive bladder cancer, suggesting it could reach blockbuster status by 2030 due to the larger target market compared to JELMYTO.
H.C. Wainwright maintained that UroGen could achieve cash flow-positive status in the second half of 2026, with ZUSDURI uptake expected to accelerate in late 2025 and early 2026. With a market capitalization of $821 million and analyst consensus strongly bullish at 1.5 (where 1 is Strong Buy), investors can access detailed financial analysis and 12 additional ProTips through InvestingPro’s comprehensive research reports.
In other recent news, UroGen Pharma reported its second-quarter 2025 earnings, showing a net loss of $1.50 per share, which was larger than the anticipated loss of $0.83 per share. Despite this, the company posted net product revenues of $24.2 million, surpassing the forecasted $23.13 million and marking an 11% increase compared to the same period last year. Following the earnings report, Guggenheim raised its price target for UroGen Pharma to $32.00 from $30.00, while maintaining a Buy rating. Guggenheim emphasized UroGen’s focus on the launch of Zusduri, a treatment approved in June for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The firm sees Zusduri as a significant opportunity in a U.S. market potentially worth $5 billion, with expectations of over $1 billion in peak sales. These developments reflect UroGen’s strategic efforts in expanding its market presence and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.